Abstract: Embodiments of the disclosure include methods and compositions related to treating an individual for HER2+ positive cancer with an appropriate treatment based on outcome of a multiparameter classifier. The methods allow for identification of HER2+ individuals that are suitable to avoid chemotherapy, in specific embodiments. Methods of the disclosure also allow for identification of HER2+ individuals that should not avoid chemotherapy. In specific embodiments, the multiparameter classifier identifies whether there is (1) a ratio of HER2 amplification, relative to a control probe, of greater than or equal to 4.5; (2) a HER2 expression level score of 3+, as determined by immunohistochemistry, in at least 90% of breast cancer cells; (3) whether there is a HER2-enriched molecular subtype; and (4) whether the individual has a wildtype PIKC3A gene.

Abstract: Embodiments provide visual programming constructs including icons representing conditions and actions for processing incoming data streams. A user selects icons corresponding to at least one of the conditions and at least one of the actions to define a rule. The selected condition relates to at least one element possibly present in the incoming data stream. Without compilation of the rule, at least one incoming data stream is analyzed based on the condition to detect a presence of the element within the incoming data stream. The action is performed based on the analysis. In some embodiments, formatting of the incoming data streams is altered according to the conditions and actions to personalize the incoming data stream.

Abstract: Embodiments provide visual programming constructs including icons representing conditions and actions for processing incoming data streams. A user selects icons corresponding to at least one of the conditions and at least one of the actions to define a rule. The selected condition relates to at least one element possibly present in the incoming data stream. Without compilation of the rule, at least one incoming data stream is analyzed based on the condition to detect a presence of the element within the incoming data stream. The action is performed based on the analysis. In some embodiments, formatting of the incoming data streams is altered according to the conditions and actions to personalize the incoming data stream.

Abstract: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.

Abstract: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.

Abstract: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.

Abstract: The present invention is directed to methods involving an AIB1 polypeptide. More particularly, the methods are directed to identifying an endocrine therapy-resistant patient, to providing a prognosis for disease-free survival of a cancer patient and to treating a cancer patient that is endocrine therapy-resistant.

Abstract: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.